A study conducted at the University of California Los Angeles Jonsson Comprehensive Cancer Center has been experimenting with a new drug, known as PD 0332991, that, when used in combination with the hormone therapy Femara (letrozole), may slow development of advanced breast cancer. According to lead researcher Dr. Richard Finn, women administered the combination therapy treatment exhibited a longer period of progression-free survival (26 months), compared to those receiving Femara alone (8 months).
While the safety and ultimateness effectiveness of this new therapy is awaiting validation by the American Cancer Society, preliminary findings are scheduled to be presented today (December 5th) at the 2012 San Antonia Breast Cancer Symposium in Texas.
To read more about this study, click here.
No comments:
Post a Comment